Dr. Tan joined Anbogen Therapeutics in 2022. Prior to joining Anbogen, Dr. Tan took a leadership role in the Medical Informatics and Translational medicine departments at ACT Genomics, a service provider that expertizes in the fields of cancer genomics and bioinformatics. Dr. Tan has years of experience in conducting clinical research with physicians in Taiwan, Hong Kong, Japan, and Singapore. He had accumulated profound knowledge, experience, and expertise in cancer genomics and precision oncology, particularly in the field of biomarker exploration. Dr. Tan earned a B.A. in Medical Technology from National Taiwan University, and a Ph.D. in Molecular and Cell Biology from National Defense Medical Center. He completed a Postdoctoral Fellowship at the Academia Sinica.